AtheroNova Receives Russia’s Approval for Phase I Clinical Trials
May 09, 2013
May 09, 2013
AtheroNova Inc. , a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, has spent the last few months building up its scientific team ahead of clinical trials. And with Russia’s approval secured, the company is now ready to begin proving AHRO-001.AHRO-001 is a novel drug for the treatment and prevention of atherosclerosis. Rather than just targeting cholesterol levels like Pfizer Inc.’s (NYSE: PFE) Lipitor® statin or Merck & Co.’s (NYSE: MRK) non-statin Zetia®, the company’s drug works by using a pharmacological compound to reduce cholesterol levels as well as potentially regress plaque deposits.AHRO-001 is AtheroNova’s first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain…
View original post 58 more words
Advertisements
